GYY4137, a Slow-Releasing Hydrogen Sulfide Donor, Attenuates Skeletal Muscle Abnormalities in a Murine Model of Duchenne Muscular Dystrophy
- PMID: 40476490
- DOI: 10.1089/ars.2024.0702
GYY4137, a Slow-Releasing Hydrogen Sulfide Donor, Attenuates Skeletal Muscle Abnormalities in a Murine Model of Duchenne Muscular Dystrophy
Abstract
Aims: Duchenne muscular dystrophy (DMD) is a severe, incurable X-linked genetic disorder caused by mutations in the DMD gene, leading to a deficiency of the muscle structural protein, dystrophin, which results in damage to skeletal and cardiac muscles. Altered expression of enzymes that generate hydrogen sulfide (H2S) has been demonstrated in dystrophic muscles, however, the exact role of this gasotransmitter in DMD remains elusive. Here, we investigated the effect of the slow-releasing H2S donor (GYY4137) on the skeletal muscles of the dystrophin-deficient mdx mice. Methods and Results: Grip strength assay and the treadmill exhaustion test showed that administering the GYY4137 donor to mdx mice improved DMD-related decline in motor functions. Additionally, the H2S donor decreased the level of muscle damage markers such as lactate dehydrogenase, creatine kinase, and osteopontin (OPN). Histological, gene, and protein analyses of the dystrophic gastrocnemius and diaphragm muscles revealed reduced inflammation and fibrosis after treatment with the H2S donor. Moreover, we showed decreased necrosis with improved muscle regeneration and angiogenesis. We demonstrated that GYY4137 upregulates the levels of phosphorylated AMPKα, as well as the cytoprotective and antioxidant heme oxygenase-1, mitochondrial superoxide dismutase, and glutamate-cysteine ligase modifier subunit (Gclm). Finally, it exerted an anti-apoptotic effect by reducing cleaved caspase-3 and caspase-3 and increasing AKT phosphorylation. Innovation and Conclusion: The administration of GYY4137 improves exercise capacity and ameliorates the markers of inflammation, fibrosis, oxidative stress, apoptosis, and necrosis in the skeletal muscles of mdx animals pointing out its possible therapeutic use in DMD pathology. Antioxid. Redox Signal. 43, 115-137.
Keywords: DMD; H2S; fibrosis; inflammation; mdx mice; therapeutic gasotransmitter.
Similar articles
-
Inhibition of mitochondrial fission protein Drp1 ameliorates skeletal myopathy in the D2-mdx model of Duchenne muscular dystrophy.Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C307-C324. doi: 10.1152/ajpcell.01009.2024. Epub 2025 Jun 16. Am J Physiol Cell Physiol. 2025. PMID: 40522885 Free PMC article.
-
Transcriptomic profiling of skeletal muscle in the DMDmdx rat model of Duchenne muscular dystrophy.Sci Rep. 2025 Aug 11;15(1):29312. doi: 10.1038/s41598-025-14756-9. Sci Rep. 2025. PMID: 40790324 Free PMC article.
-
Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model.Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2018342118. doi: 10.1073/pnas.2018342118. Proc Natl Acad Sci U S A. 2021. PMID: 33627403 Free PMC article.
-
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Free PMC article.
-
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.Cochrane Database Syst Rev. 2021 Dec 1;12(12):CD013720. doi: 10.1002/14651858.CD013720.pub3. Cochrane Database Syst Rev. 2021. PMID: 34850383 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials